Ten flavonoids (1-10), including a new glycoside (nevadensin-7-sambubioside, 7), together with a phenylpropanoid glycoside (11) were isolated from Lysionotus pauciflorus. Their structures were elucidated by a combination of spectroscopic methods and comparing with literature data. Five compounds (1, 3,  4, 8, and 9) were obtained from the family Gesneriaceae for the first time. The new compound was evaluated in vitro for anticholinesterase activities against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), but was found to be inactive.
The genus Lysionotus, family Gesneriaceae, consists of about 30 species of which about 28 occur in China [1] . L. pauciflorus Maxim, called 'Shi Diao Lan' in Chinese, is widespread in southern China. It has been applied in the treatment of lymph node tuberculosis, cough with tachypnoea, rheumatic pains and cancer as a Traditional Chinese Medicine [2] . Only L. denticulosus and L. pauciflorus have been phytochemically studied, in particular the latter. Previous phytochemical investigations of L. pauciflorus have led to the identification of nearly 40 compounds, including flavonoids [3a] , flavonoid glycosides [3b], sterols [1,3c] , ursolic acid [3d], sesquiterpene [3e], phenylpropanoid [4] , and some simple phenolic compounds [5a] . Here we report the isolation of a new flavonoid glycoside (7) , together with 10 known compounds from L. pauciflorus, and the anticholinesterase activity evaluation of the new compound. The known compounds 1-6 and 8-11 were identified as: 4-hydroxy-2,4-dimethoxydihydrochalcone (1) [5b], demethoxysudachjtin (2) [5c], acerosin (3) [5d], 5,7,3,4tetrahydroxy-6,8-dimethoxyflavone (4) [6] , nevadensin (5) [5a] , 5-hydroxy-6,8,4-trimethoxy flavone-7-O-β-D-glucopyranosyl (6) [5a], ikarisoside B (8) [7] , 2-O-rhamnosylicariside Ⅱ(9) [8] , lysioside C (10) [3c], and acteoside (11) [9a] . strong HMBC correlation between the anomeric proton at δ 5.48 
Extraction and isolation:
The air-dried and powdered whole plants (5.0 kg) of L. pauciflorus were extracted with 95% ethanol 3 times at room temperature for 72 h each time, and the combined extracts were concentrated under vacuum. The residue was suspended in distilled water, and then partitioned with light petroleum, EtOAc, and n-BuOH, respectively.
The EtOAc-soluble fraction was concentrated to dryness under reduced pressure and the resulting extract (44 g) was subjected to silica gel CC to yield 10 portions (A~J). Portion H (1.9 g) was then separated by repeated MCI CHP 20P resin CC to obtain 3 subfractions H5a-H5c. Fraction H5a was further purified by preparative TLC to obtain compound 1 (27 mg). Portion J (1.8 g) was subjected to MCI CHP 20P resin CC to obtain 6 fractions (J1-J6). Compound 2 (385 mg) was crystallized as yellow needles from fraction J5. Portion K (1.8 g) was eluted on Sephadex LH-20 CC to obtain 6 fractions (K1-K6). Fraction K2 (326 mg) was applied to MCI CHP 20P resin CC to afford 3 sub-fractions (K2a-K2c). Sub-fraction K2c (59 mg) was further purified by preparative TLC to yield 3 (8 mg). Fraction K3 (172 mg) was purified by preparative TLC to obtain 2 sub-fractions (K3a-K3b). K3a (40 mg) was further applied to a Toyopearl HW-40 column to provide compound 4 (15 mg). Portion L (16.6 g) was sectioned into 7 fractions (L1-L7) upon the result of MCI CHP 20P resin CC. Fraction L6 (2.13 g) was eluted on Sephadex LH-20 CC to obtain 10 sub-fractions (L6a-L6j). Subfraction L6a (255 mg) was purified by repeated preparative TLC to yield compound 9 (16 mg). Portion N (4.8 g) was subjected to MCI CHP 20P resin CC to yield 8 fractions (N1-N8). Fraction N2 (445 mg) was purified by preparative TLC to obtain 2 fractions (N2a-N2b). Fraction N2a (116 mg) was further purified by Toyopearl HW-40 CC to provide compound 11 (51 mg). Fraction N5 (231 mg) was purified by preparative TLC to obtain 2 fractions (N5a-N5b). N5b (64 mg) was further purified by Toyopearl HW-40 CC to yield compound 10 (36 mg). Fraction N6 (231 mg) was purified by preparative TLC to obtain 2 su-fractions (N6a-N6b). N6b (143 mg) was further purified by Toyopearl HW-40 CC to obtain compound 7 (53 mg). Fraction N8 (79 mg) was subjected to preparative TLC to yield compound 8 (27 mg).
The n-BuOH solution was concentrated to dryness under reduced pressure and the resulting extract (372 g) was sectioned into 4 fractions. The 60% EtOH fraction (65 g) was subjected to silica gel CC to provide 9 portions (A~I). Portions A (0.9 g) and C (2.9 g) were fractionated on a MCI CHP 20P resin column to obtain 2 fractions (A1-A2) and 4 fractions (C1-C4), respectively. Compound 5 (516 mg) was crystallized from fraction A2, while compound 6 (65 mg) was crystallized from fraction C4. Nevadensin-7-sambubioside (7) Yellow amorphous powder. 1 
AChE and BuChE inhibitory activities:
The AChE inhibitory activity of 7 was evaluated by a microplate assay based on Ellman's method [9f], with modification. Galanthamine was used as positive control.
